Published: Sep 2017
ACE Report #10352
Ace Report Cover Cannabis

Oral THC/CBD spray provides neuropathic pain control in MS patients, with mild/moderate side effects

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:N/A

Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial

Clin Ther. 2007 Sep;29(9):2068-79

Contributing Authors: TJ Nurmikko DJ Rog CA Young

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.